



Stabilis



Co-trimoxazole



Торгова назва

Bactrim	Італія, Аргентина, Бразилія, Венесуела, Греція, Колумбія, Марокко, Нідерланди, Об'єднані Арабські Емірати, Польща, Саудівська Аравія, Словенія, Сполучені Штати Америки, Франція
Bactrimel	Венесуела, Греція, Нідерланди
Biseptol	Польща, Словенія
Cotrim	Іран, Німеччина, Португалія, Словенія, Чилі
Cotrimoxazol	Португалія, Чилі
Cotrizol	Аргентина
Danferane	Аргентина
Eusaprim	Австрія, Бельгія, Люксембург, Нідерланди, Швеція
Novidrine	Аргентина
Pisatrina	Мексика
Septtrin	Іран, Ірландія, Греція, Об'єднані Арабські Емірати, Польща, Португалія, Саудівська Аравія, Чилі
Soltrim	Іспанія
Spectrex	Аргентина



Стійкість в розчинах

		0,8/1,6 mg/ml	2-8°C		7			4922
		0,6/3,2 mg/ml	23-25°C		24			1197
		0,64 / 3,2 mg/ml	23°C-25°C		48			442
		0,8 / 4 mg/ml	23°C-25°C		14			442
		1,07 / 5,33 mg/ml	23°C-25°C		2			442
		1,6 / 8 mg/ml	23°C-25°C		1			442
		1,6/8 mg/ml	23-25°C		24			1197

		0,6/3,2 mg/ml	23-25°C		24			1197
		0,64 / 3,2 mg/ml	23°C-25°C		48			442
		0,8 / 4 mg/ml	23°C-25°C		24			442
		1,07 / 5,33 mg/ml	23°C-25°C		4			442
		1,6 / 8 mg/ml	23°C-25°C		1			442
		1,6/8 mg/ml	23-25°C		24			1197
	RL	0,6/3,2 mg/ml	23-25°C		12			1197
	RL	1,6/8 mg/ml	23-25°C		24			1197
		0,6/3,2 mg/ml	23-25°C		24			1197
		1,6/8 mg/ml	23-25°C		24			1197
		0,8/1,6 mg/ml	2-8°C		2			4922
PVC		3.33/0.66 mg/ml	20-22°C		4			4012
PVC		4,21/0,84 mg/ml	20-22°C		4			4012
PVC		5,71/1,14 mg/ml	20-22°C		2			4012
	Ø	16/80 mg/ml	18°C-24°C		60			446



Фактори, що впливають на стабільність

				3583
				2339



Сумісність

	Co-trimoxazole : 4/0.8 mg/ml Aciclovir sodium : 5 mg/ml	336
	Co-trimoxazole Aldesleukin : 0.0338 MUI/ml	36
	Co-trimoxazole : 4/0.8 mg/ml Allopurinol sodium : 3 mg/ml	307
	Co-trimoxazole : 4/0.8 mg/ml Amifostine : 10 mg/ml	3
	Co-trimoxazole : 16/80 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	3824
	Co-trimoxazole : 0.8/4 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	921
	Co-trimoxazole : 4/0.8 mg/ml Anidulafungin : 0.5 mg/ml	1982

		Co-trimoxazole : 3.2/0.64 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Co-trimoxazole : 4/0.8 mg/ml Aztreonam : 40 mg/ml		99
		Co-trimoxazole : 4/0.8 mg/ml Bivalirudin : 5 mg/ml		1713
		Co-trimoxazole : 3.2 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Co-trimoxazole : 16/80 mg/ml Caffeine : 10 mg/ml		3964
		Co-trimoxazole : 4/0,8 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml Cefazolin sodium : 41.6 mg/ml		4254
		Co-trimoxazole : 4/0,8 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Co-trimoxazole : 4/0,8 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Co-trimoxazole : 4/0,8 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Co-trimoxazole : 0.8/4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Co-trimoxazole : 0.8/4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Co-trimoxazole		3583
		Co-trimoxazole		3583
		Co-trimoxazole	RL	1197
		Co-trimoxazole : 0.8/4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Co-trimoxazole : 80/16 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Co-trimoxazole : 0.21 & 0.63 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Co-trimoxazole		3583
		Co-trimoxazole : 0.8/4 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Co-trimoxazole : 0.64/3.2 mg/ml Defibrotide : 8 mg/ml		3728
		Co-trimoxazole		2162
		Co-trimoxazole Daunorubicin/cytarabine liposomale		4354
		Co-trimoxazole Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Co-trimoxazole : 4/0.8 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Co-trimoxazole		3583
		Co-trimoxazole Dimenhydrinate		2087
		Co-trimoxazole : 0.8/4 mg/ml		301

		Co-trimoxazole : 0,8/4 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
		Co-trimoxazole : 4/0.8 mg/ml Docetaxel : 0.9 mg/ml		1754
		Co-trimoxazole : 0.64/3.2 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Co-trimoxazole : 4/0.8 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Co-trimoxazole : 0.8/4 mg/ml Filgrastim : 30 µg/ml		244
		Co-trimoxazole : 0,76/3,81 mg/ml		4440
		Co-trimoxazole : 0.8/4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Co-trimoxazole : 0.8/1.6 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Co-trimoxazole : 0.8/4 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Co-trimoxazole : 0.8/4 mg/ml Fluconazole : 2 mg/ml		256
		Co-trimoxazole : 0.8/4 mg/ml		1415
		Co-trimoxazole : 16 mg/ml Fluconazole : 2 mg/ml		496
		Co-trimoxazole : 0.8/4 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Co-trimoxazole Foscarnet sodium : 24 mg/ml		73
		Co-trimoxazole : 2,6/0,53 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Co-trimoxazole Foscarnet sodium		3662
		Co-trimoxazole : 4/0,8 mg/ml Gallium nitrate : 1 mg/ml		91
		Co-trimoxazole : 0.8/4 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Co-trimoxazole : 4/0.8 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml Heparin sodium : 208 UI/ml		4254
		Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml Heparin sodium : 208 UI/ml		4254
		Co-trimoxazole : 4/0.8 mg/ml Hetastarch : 60 mg/ml		1721
		Co-trimoxazole : 4/0.8 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml Insulin : 1 UI/ml		4254
		Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml Insulin : 1 UI/ml		4254
		Co-trimoxazole : 80/16 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Co-trimoxazole : 4/0.8 mg/ml Labetalol hydrochloride : 1 mg/ml		386

		Co-trimoxazole : 0.8/4 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Co-trimoxazole : 0.8/4 mg/ml Linezolid : 2 mg/ml		1607
		Co-trimoxazole Linezolid		3560
		Co-trimoxazole : 0.8/4 mg/ml Linezolid : 2 mg/ml		1925
		Co-trimoxazole : 0.8/4 mg/ml Lorazepam : 0.33 mg/ml		186
		Co-trimoxazole : 0.8/40 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Co-trimoxazole : 0.8/4 mg/ml Melfalan : 0.1 mg/ml		169
		Co-trimoxazole : 80/16 mg/ml Meropenem : 50 mg/ml		4319
		Co-trimoxazole : 0.8/4 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Co-trimoxazole : 4/0.8 mg/ml Morphine sulfate : 1 mg/ml		405
		Co-trimoxazole : 16/80 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Co-trimoxazole Naloxone hydrochloride : 0.4 mg/ml		3408
		Co-trimoxazole : 0.8/1.6 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Co-trimoxazole : 0.8/1.6 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Co-trimoxazole : 0.8/4 mg/ml Oritavancin : 0.8 >> 2 mg/ml		3152
		Co-trimoxazole : 3.2/0.64 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Co-trimoxazole Pantoprazole sodium		2090
		Co-trimoxazole : 16/80 mg/ml Paracetamol : 10 mg/ml		4742
		Co-trimoxazole : 0.8/4 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Co-trimoxazole : 4/0.8 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Co-trimoxazole : 12 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Co-trimoxazole : 0.8/4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Co-trimoxazole : 0.8/4 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Co-trimoxazole Rocuronium bromide		3564
		Co-trimoxazole : 16/80 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Co-trimoxazole : 0.8/4 mg/ml Sargramostim : 10 µg/ml		335

		Co-trimoxazole Sodium bicarbonate		3583
		Co-trimoxazole : 16/8 mg/ml Tacrolimus : 1000 µg/ml		479
		Co-trimoxazole : 0.8/4 mg/ml Teniposide : 0.1 mg/ml		905
		Co-trimoxazole : 16/80 mg/ml Thiopental sodium : 25 mg/ml		3767
		Co-trimoxazole : 0.8/4 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Co-trimoxazole		3583
		Co-trimoxazole : 0.8/4 mg/ml Thiotepa : 1 mg/ml		249
		Co-trimoxazole : 3.2/0.64 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Co-trimoxazole : 0.16/0.8 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Co-trimoxazole : 0.16/0.8 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Co-trimoxazole : 0.53/2.6 mg/ml Zidovudine : 4 mg/ml		337



Шлях введення



Список літератури

	Тип	Публікація
3	журнал	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	журнал	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	журнал	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	журнал	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	журнал	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.

84	журнал	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	журнал	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	журнал	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	журнал	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	журнал	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	журнал	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	журнал	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	журнал	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
256	журнал	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
299	журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	журнал	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	журнал	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
335	журнал	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	журнал	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.


337	журнал	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
384	журнал	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	журнал	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
402	журнал	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
405	журнал	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
442	журнал	Jarosinski PF, Kennedy PE, Galleli JF. Stability of a concentrated trimethoprim-sulfamethoxazole admixtures. Am J Hosp Pharm 1989 ; 46: 732-737.
446	журнал	Kaufman MB, Scavone JM, Foley JJ. Stability of undiluted trimethoprim-sulfamethoxazole for injection in plastic syringes. Am J Hosp Pharm 1992 ; 49: 2782-2783.
479	журнал	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	журнал	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	журнал	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
905	журнал	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	журнал	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1047	журнал	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	журнал	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1135	журнал	Baltz JK, Kennedy P, Minor JR, Galleli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1197	журнал	Deans KW, Lang JR, Smith DE. Stability of trimethoprim-sulfamethoxazole injection in five infusion fluids. Am J Hosp Pharm 1982 ; 39: 1681-1684.

1315	журнал	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	журнал	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	журнал	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	журнал	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1607	журнал	Trissel LA, Zhang Y, Xu QA. Incompatibility of erythromycin lactobionate and sulfamethoxazole/trimethoprim with linezolid injection. Hosp Pharm 2000 ; 35: 1192-1196.
1625	журнал	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	журнал	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	журнал	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	журнал	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	журнал	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	журнал	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	журнал	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	журнал	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	журнал	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	журнал	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	журнал	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.


2109	журнал	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2162	журнал	Holmes SE, Aldous S. Stability of cotrimoxazole in peritoneal dialysis fluid. Perit Dial Int 1990 ; 10: 157-160.
2247	журнал	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2269	журнал	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocartil with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2339	журнал	Curtis J.M, Edwards D.J. Stability of Trimethoprim in Admixtures of Trimethoprim–Sulfamethoxazole Prepared in Polyvinylchloride Bags and Glass Bottles Can J Hosp Pharm 2002 ; 55, 3: 207-211.
3012	журнал	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	журнал	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	журнал	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	журнал	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	журнал	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3560	Виробник	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3564	Виробник	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3583	Виробник	Sulfaméthoxazole triméthoprime (Bactrim®) - Résumé des caractéristiques du produit Roche 2013
3662	Виробник	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	журнал	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	журнал	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	журнал	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.

3791	Плакат	Sadou Yaye H, Burtet E, Hamel C, Aljhi R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	журнал	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	журнал	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	журнал	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4012	журнал	Khaleel I, Tabish R Zaidi S, Shastri M, Suji Eapen M, Chiau Ming L, Wanandy T, P Patel R. Investigations into the physical and chemical stability of concentrated co-trimoxazole intravenous infusions. EJHP 2018 ; 25, e2
4254	журнал	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	журнал	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4354	Плакат	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019
4440	журнал	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4654	Плакат	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	журнал	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4922	журнал	Wanandy T, Handley SA, Le TTA, Lau WY, Turner ME, Wiese MD. Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions. J Allergy Clin Immunol Pract 2024 13, 2: 343-352.

Stabilis



Co-trimoxazole



Стабільність фармацевтичних препаратів

		2000/400 mg ® = ?	Oral Mix® >> 50 mL	25°C		14			4638
		2000/400 mg ® = ?	Oral Mix SF® >> 50 mL	25°C		14			4638
		2000/400 mg ® = ?	Oral Mix® >> 50 mL	5°C		90			4638
		2000/400 mg ® = ?	Oral Mix SF® >> 50 mL	5°C		14			4638
		100/20 mg ® = ?	Oral Mix® >> 2,5 mL	25°C		14			4638
		100/20 mg ® = ?	Oral Mix SF® >> 2,5 mL	25°C		7			4638
		100/20 mg ® = ?	Oral Mix® >> 2,5 mL	5°C		90			4638
		100/20 mg ® = ?	Oral Mix SF® >> 2,5 mL	5°C		90			4638



Список літератури

	Тип	Публікація
4638	журнал	St-Jean I, Friciu M, Monfort A, MacMahon J, Forest J-M, Walker S, Leclair G. Stability of Extemporaneously Compounded Suspensions of Trimethoprim and Sulfamethoxazole in Amber Plastic Bottles and Amber Plastic Syringes. Can J Hosp Pharm 2021;74(4):327-33



СЛОВНИК

	Антибіотик		ін'єкція
	Торгова назва		Стійкість в розчинах
	Контейнер		молекула
	Концентрація		температура
	Зберігання		Тривалість стабільності
	Біоподібний		суперечливі дані
	Список літератури		скло
	Вода для ін'єкцій		Берегти від світла
	День		Натрію хлорид 0,9%
	Не визначено		годину
	Глюкоза 5%	RL	Розчин лактату Рінгера
	Натрію хлорид 0,45%		NaCl 0.9% + фенол 0.4%
	Полівініл хлорид		світло
	Поліпропіленовий шприц		Жодного
	Фактори, що впливають на стабільність		Розчинник
	NaHCO3		Спонукає
	хімічна деградація		Покращена стабільність
	Сумісність		З'єднання
	сумісний		Миттєві опади
	Несумісні		Помутніння через годину
	NaCl 0,45% Глюкоза 2,5%		Підзора не сумісність
	Неуточнена не сумісність		Dianéal® PD2 4.25% glucose (Baxter)
	Негайне помутніння		Глюкоза 10%
	Парентеральне харчування (бінарна су		Парентеральне харчування (ліпідами)
	Опади через 4 год		специфічний розчинник
	Опади через 1 год		Шлях введення
	Внутрішньовенне вливання		Внутрішньом'язове
	Список літератури		Розчин для перорального застосування
	Стабільність фармацевтичних препарат		Origine
	допоміжна речовина		пластиковая пляшка



powder



шприц



Словник